Cargando…

Immune responses triggered by HIV/AIDS vaccine candidates, derived from MVA-B, with deletions in several immune regulatory genes

Detalles Bibliográficos
Autores principales:	García-Arriaza, J, Arnáez, P, Gómez, CE, Esteban, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441745/ http://dx.doi.org/10.1186/1742-4690-9-S2-P302

Ejemplares similares

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways
por: García-Arriaza, Juan, et al.
Publicado: (2013)

Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C
por: Gómez, C, et al.
Publicado: (2012)

Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions
por: García-Arriaza, Juan, et al.
Publicado: (2010)

P17-07. Insertion of a vaccinia virus host range (hr) gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens
por: Najera, JL, et al.
Publicado: (2009)

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
por: Pérez, Patricia, et al.
Publicado: (2020)

Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens
por: Perdiguero, Beatriz, et al.
Publicado: (2012)

A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses
por: García-Arriaza, Juan, et al.
Publicado: (2011)

P17-17. Newborn mice vaccination with rBCG:HIVA + MVA:HIVA enhances HIV-1-specific immune responses. Influence of age and immunization routes
por: Saubi, N, et al.
Publicado: (2009)

IL-12 plus CTB in intranasal DNA-MVA schemes improved magnitude and quality of both systemic and mucosal HIV cellular immune responses
por: Rodriguez, AM, et al.
Publicado: (2012)

A prime-boost immunization with rBCG expressing HIV-1 Gag, RT and gp120 and SAAVI MVA-C elicits immune responses in blood and MALT of rhesus macaques
por: Chege, GK, et al.
Publicado: (2012)

Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
por: Gómez, Carmen Elena, et al.
Publicado: (2012)

P19-53 LB. Priming with recombinant BCG expressing HIV-1 Gag or RT and boosting with recombinant MVA induces an effective immune response in mice
por: Stutz, H, et al.
Publicado: (2009)

P14-14 LB. A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA
por: Bakari, M, et al.
Publicado: (2009)

Pre-existing humoral immunity in military smallpox vaccinees temporally effects MVA-vectored transgene expression in dendritic cells
por: Ngauy, V, et al.
Publicado: (2012)

Correction: Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
por: Gómez, Carmen Elena, et al.
Publicado: (2012)

Correction: Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
por: Gómez, Carmen Elena, et al.
Publicado: (2012)

Homology of HIV-1 Indian subtype C tat gene with other subtypes correlates with the induction of potent cross clade immune responses following immunization with HIV-1 Indian subtype C mutated and codon optimized tat DNA/MVA vaccine in mice
por: Qureshi, Huma, et al.
Publicado: (2006)

DNA/MVA Vaccines for HIV/AIDS
por: Iyer, Smita S., et al.
Publicado: (2014)

An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design
por: Pérez, Patricia, et al.
Publicado: (2019)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

A single dose of SAAVI MVA-C reboosts rhesus macaques after more than 3 years post DNA-MVA prime-boost vaccination
por: Chege, GK, et al.
Publicado: (2012)

Induction of HIV-1 Gag-specific memory T cells in Chacma baboons by MVA prime and VLP boost vaccine regimen
por: Singh, V, et al.
Publicado: (2012)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
por: Munseri, P, et al.
Publicado: (2012)

Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation
por: Kumar, R, et al.
Publicado: (2012)

P19-19. MVA vaccines are efficiently cross-presented by DCs and do not enhance HIV replication in DC/T cell cultures
por: Brandler, S, et al.
Publicado: (2009)

Impact of timing HAART initiation on immune status and clinical course in the cohort of the German competence network for HIV/AIDS
por: Plettenberg, A, et al.
Publicado: (2010)

Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults
por: Mensah, Victorine, et al.
Publicado: (2014)

Loading dendritic cells from HIV-1 infected patients with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses
por: Climent, N, et al.
Publicado: (2012)

P14-03. HIV-specific T-lymphocyte proliferative responses induced by a multigene multiclade HIV-1 DNA/MVA heterologous vaccine in Tanzanian volunteers
por: Aboud, S, et al.
Publicado: (2009)

CD161+ regulatory t cells in immune regulation
por: Duurland, Chantal, et al.
Publicado: (2014)

Immunization strategies to elicit mucosal immune response of HIV
por: Shi, Yinghui
Publicado: (2006)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
por: Ahmed, T, et al.
Publicado: (2012)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
por: Borthwick, NJ, et al.
Publicado: (2012)

P05-03. The use of immune complexes to enhance antibody responses against neutralizing epitopes on HIV envelope
por: Hioe, CE, et al.
Publicado: (2009)

P02-04. Multimeric soluble CD40 ligand efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus strains
por: Najera, J, et al.
Publicado: (2009)

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
por: Podola, L, et al.
Publicado: (2012)

Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization
por: C. Guardo, Alberto, et al.
Publicado: (2017)

In vitro effect of immune regulatory cytokines on vitiligo pathogenesis
por: Singh, Mala, et al.
Publicado: (2014)

Antigen-specific T lymphocyte responses elicited by a DNA – MVA HIV CN54gp140 immunization regime are significantly altered by the TLR4 adjuvant GLA
por: McKay, PF, et al.
Publicado: (2012)

Preclinical evaluation of MVA-MUC1-IL2 in combination with chemotherapy in murine models
por: De Meyer, Micaël, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_drmv43onj2ct4kb3tm79jb7ipo